Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $20.00

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of analysts have recently weighed in on the stock. Robert W. Baird upped their target price on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Morgan Stanley lifted their price objective on Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th.

Institutional Trading of Contineum Therapeutics

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in Contineum Therapeutics during the 4th quarter valued at about $43,000. Strs Ohio purchased a new stake in Contineum Therapeutics during the 1st quarter valued at about $27,000. Royal Bank of Canada grew its position in Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after purchasing an additional 2,454 shares during the last quarter. Bank of America Corp DE grew its position in Contineum Therapeutics by 500.0% during the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company’s stock valued at $85,000 after purchasing an additional 6,030 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in Contineum Therapeutics during the 2nd quarter valued at about $43,000.

Contineum Therapeutics Price Performance

NASDAQ:CTNM opened at $11.86 on Friday. The firm’s 50-day moving average price is $13.13 and its 200-day moving average price is $12.94. The company has a market capitalization of $443.45 million, a PE ratio of -6.08 and a beta of 0.89. Contineum Therapeutics has a 1-year low of $3.57 and a 1-year high of $16.33.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.16. Equities analysts anticipate that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.